Core Insights - Autonomix Medical, Inc. announced significant improvements in quality of life for patients with severe pancreatic cancer pain following a targeted ablation therapy, as evidenced by a post-hoc exploratory subgroup analysis of its proof-of-concept study [1][4][5] Study Findings - The analysis utilized the EORTC QLQ-C30 scale to assess quality of life, symptom burden, and functionality across various patient subgroups, including those with different tumor stages and metastatic statuses [1][4] - Late-stage patients demonstrated substantial improvements, indicating that the ablation therapy provided clinically meaningful changes even in advanced disease [1][4] - Average symptom scores improved by 14.53 points at 4–6 weeks and 26.07 points at 3 months, with functionality and global quality of life also showing significant enhancements [7][10] - Patients with Stage 4 pancreatic cancer experienced a 32.48 point improvement in symptoms and an 11.85 point functional gain by 4–6 weeks, with sustained benefits at 3 months [7][10] Clinical Trial Insights - The findings will inform the design and patient selection for Autonomix's upcoming U.S.-based multicenter clinical study, set to begin in 2026, which will formally evaluate pain relief and quality-of-life outcomes [2][6] - The initial proof-of-concept study enrolled 20 patients, with 100% of responding patients achieving opioid-free status at 3 months post-procedure [10][17] Future Directions - Based on the positive results from the proof-of-concept study, Autonomix is expanding its research to include additional visceral cancers and earlier-stage pancreatic cancers, aiming to address a broader market for interventional cancer pain management [11][12]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [2][3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3][4] Technology and Applications - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] Upcoming Events - The President and CEO of Autonomix, Brad Hauser, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025, at 1:00 PM ET [2][3] - The webinar will include a question and answer session, allowing participants to pre-submit questions [3]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3] Technology and Applications - The initial focus of the technology is on treating pain, specifically targeting pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4] Upcoming Events - Autonomix will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, scheduled for August 19-21, 2025, with the presentation taking place on August 21, 2025, at 2:20 PM ET [1]